Evidence map›Paper›PMID 36901737›Full record

ReviewInternational journal of molecular sciences2023

Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies.

Yu-Lei Chen, Xin-Xin Xie, Ning Zhong, Le-Chang Sun, Duanquan Lin, Ling-Jing Zhang, Ling Weng, Tengchuan Jin, Min-Jie Cao

Open access · goldFull text readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A short guide on blue fluorescent proteins: limits and perspectives.Applied microbiology and biotechnology · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yu-Lei ChenCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.ORCID 0000-0003-2893-6540
Xin-Xin XieCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Ning ZhongCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Le-Chang SunCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.ORCID 0000-0002-7083-1622
Duanquan LinCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Ling-Jing ZhangCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Ling WengCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Tengchuan JinInstitute of Health and Medicine, Hefei Comprehensive National Science Center, CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science & Technology of China, Hefei 230007, China.ORCID 0000-0002-1395-188X
Min-Jie CaoCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Jimei University · CNUniversity of Science and Technology of China · CN

Funding

National Key R&D Program of China 2018YFD0901004Natural Science Foundation of Fujian Province 2021J01838
6 · The paper itself

Abstract

Since the discovery of fluorescent proteins (FPs), their rich fluorescence spectra and photochemical properties have promoted widespread biological research applications. FPs can be classified into green fluorescent protein (GFP) and its derivates, red fluorescent protein (RFP) and its derivates, and near-infrared FPs. With the continuous development of FPs, antibodies targeting FPs have emerged. The antibody, a class of immunoglobulin, is the main component of humoral immunity that explicitly recognizes and binds antigens. Monoclonal antibody, originating from a single B cell, has been widely applied in immunoassay, in vitro diagnostics, and drug development. The nanobody is a new type of antibody entirely composed of the variable domain of a heavy-chain antibody. Compared with conventional antibodies, these small and stable nanobodies can be expressed and functional in living cells. In addition, they can easily access grooves, seams, or hidden antigenic epitopes on the surface of the target. This review provides an overview of various FPs, the research progress of their antibodies, particularly nanobodies, and advanced applications of nanobodies targeting FPs. This review will be helpful for further research on nanobodies targeting FPs, making FPs more valuable in biological research.

Indexed as

Single-Domain AntibodiesAntibodies, MonoclonalAntigensGreen Fluorescent ProteinsImmunoglobulin Heavy ChainsRed Fluorescent ProteinAntibodies, MonoclonalAntigensGreen Fluorescent ProteinsImmunoglobulin Heavy ChainsRed Fluorescent ProteinSingle-Domain Antibodiesapplicationfluorescent proteinmonoclonal antibodynanobodyresearch progress

Identifiers

PMID36901737
PMCPMC10002328
OpenAlexW4321523312

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read8
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.